Get started
Author

Theresa Samuel Nached

Observed name: T. Samuel Nached
ORCID: 0009-0002-5516-2114
Observed ORCID: 0009-0002-5516-2114
OpenAlex ID: A5117577558
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
2026 · Keun-Wook Lee, Elena Elimova, et al. · Clinical Cancer Research · 1
PDF
303MO Zanidatamab (Zani) + chemotherapy (Chemo) for patients (Pts) with HER2-expressing metastatic breast cancer (mBC): Final results of a phase I trial
2025 · P.L. Bedard, S-A. Im, et al. · ESMO Open · 1
PDF
Supplementary Table S1 from Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
2026 · Keun-Wook Lee, Elena Elimova, et al.
Supplementary Figure S2 from Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
2026 · Keun-Wook Lee, Elena Elimova, et al.
Data from Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
2026 · Keun-Wook Lee, Elena Elimova, et al.
Supplementary Figure S1 from Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
2026 · Keun-Wook Lee, Elena Elimova, et al.
Supplementary Table S3 from Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
2026 · Keun-Wook Lee, Elena Elimova, et al.
Supplementary Table S2 from Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
2026 · Keun-Wook Lee, Elena Elimova, et al.
PP01.25: Safety and Preliminary Efficacy of Zanidatamab in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer (NSCLC): Subgroup Analysis from a Phase 1 Study
2026 · Do-Youn Oh, Tae Min Kim, et al. · Journal of Thoracic Oncology
Works count: 9
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type